<DOC>
	<DOCNO>NCT01909843</DOCNO>
	<brief_summary>This Phase I , single-centre , open label study evaluate occurrence subsequent reversibility prevention , bronchoconstriction follow single repeat oral inhalation ALX-0171 adult hyperresponsive airway . This phase I study exploratory study serf evaluate occurrence reversibility bronchoconstriction upon inhalation ALX-0171 . The study open label trial sequential administration regimen placebo verum plan study subject . Each subject start treatment single dose ALX-0171 placebo ( = formulation buffer ) follow escalate dos ALX-0171 verum . Eventually second administration ALX-0171 placebo may take place end study ( define per protocol ) .</brief_summary>
	<brief_title>ALX-0171 Safety Study Adults With Hyperresponsive Airways</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Adult male female subject age 1860 year ( include ) . 2 . Subjects must demonstrate PC20 ( concentration agonist inhale substance lead fall FEV1 ≥20.0 % personal best visit ) response methacholine ( MCh ) concentration &gt; 1 mg/mL ≤ 8 mg/mL screening . 3 . Subjects concomitant treatment except 1. medication effect hyperresponsiveness , bronchoconstriction lung function parameter 2. respiratory medication subject able discontinue current treatment study period take account respective washout period list protocol . 3. shortacting bronchodilator certain condition specify protocol . 4 . Screening forced expiratory volume ( FEV1 ) value &gt; 60.0 % predict normal value washout respiratory medication list protocol . 5 . Subject inform verbally write objective clinical trial , method , anticipate benefit potential risk discomfort may expose , give write consent participation trial prior trial start trialrelated procedure . 6 . Body weight accord Body Mass Index ≥ 18.5 ≤ 29.0 kg/m² . 7 . Nonsmokers exsmokers stop smoke least 1 year prior start clinical study . No history smoke 10 pack year . 8 . Ability inhale appropriate manner . 9 . Female subject childbearing potential male subject must agree use appropriate method contraception specify protocol . 1 . Subjects predose baseline FEV1 measurement first day ( i.e . prior first inhalation ALX0171 placebo ) equal 60.0 % predict FEV1 value . 2 . Presence clinically significant disease asthma , hyperresponsive airway atopic disease ( cardiovascular , renal , hepatic , gastrointestinal , haematological , neurological , genitourinary , autoimmune , endocrine , metabolic , etc . ) , , opinion investigator , may either put subject risk participation trial , disease may influence result study subject 's ability take part . 3 . Presence relevant pulmonary disease ( except asthma ) history thoracic surgery . 4 . History current evidence clinically relevant allergy drug . 5 . Any absolute relative contraindication methacholine challenge : e.g. , severe moderate airflow limitation ( FEV1 ≤ 60.0 % predict &lt; 1.5 L ) , heart attack stroke last 3 month , uncontrolled hypertension , know aortic aneurysm , current use cholinesterase inhibitor medication . 6 . Hospitalisation emergency room treatment acute asthma 3 month prior screen , screen start treatment period . 7 . Hospitalisation longer 24 hour management asthma exacerbation within precede 3 month screen visit intubation ( ever ) name cause . 8 . History allergic reaction active inactive ingredient nebuliser solution . 9 . ECG abnormalities clinical relevance . 10 . Clinically relevant abnormal heart rate and/or blood pressure judge investigator . 11 . Proneness orthostatic dysregulation , fainting , blackout . 12 . History ( within last 5 year ) presence malignancy except basalioma . 13 . Clinically relevant abnormality clinical chemical , haematological laboratory variable . 14 . Chronic clinically relevant acute infection . 15 . Clinically relevant positive result follow virology test : Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) 1 , HIV 2 antibody . 16 . Positive drug screen . 17 . History previous administration ALX0171 medication target Fprotein ( e.g . palivizumab ) inhale biologic . In case use biologics : 6 month , time duration pharmacodynamic effect , 10 time halflife respective drug , whatever longer , first trial medication administration . 18 . History presence alcohol drug abuse . 19 . Planned donation germ cell , blood , organ , bone marrow course trial within 6 month thereafter . 20 . Participation another clinical trial investigational drug within last month ( define 1 month last visit previous trial Informed Consent Form ( ICF ) signature current trial ) . 21 . Blood donation within last 30 day screen . 22 . Lack ability willingness give inform consent . 23 . Anticipated nonavailability trial visits/procedures . 24 . Anticipated lack willingness inability cooperate adequately . 25 . Vulnerable subject ( e.g. , person keep detention ) . 26 . Consumption xanthine derivates ( limited , caffeine , theophylline , chocolate ) 6 hour first procedure study visit . 27 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>